Ipratropium + Fenoterol Farmak

Fenoterol Hydrobromide, the active ingredient in Ipratropium + Fenoterol Farmak, is a β2‑adrenergic agonist presented as an inhalation bronchodilator for the relief of bronchospasm in asthma and chronic obstructive pulmonary disease. Ipratropium Bromide, also contained in the product, adds anticholinergic activity to enhance airway opening. GNH USA supplies Ipratropium + Fenoterol Farmak as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium + Fenoterol Farmak is a fixed‑dose inhaled bronchodilator used in obstructive airway diseases.

Asthma: improves airflow by relaxing bronchial smooth muscle and reducing cholinergic tone. Chronic obstructive pulmonary disease (COPD): provides rapid relief of bronchoconstriction and improves exercise tolerance. Bronchospasm (acute): rapidly alleviates sudden airway narrowing during attacks.

The following adverse reactions have been reported with inhaled fenoterol/ipratropium combinations.

Common Side Effects: - Cough or throat irritation. - Dry mouth. - Headache. - Tremor or shakiness. - Palpitations. - Nausea.

Serious or Rare Side Effects: - Paradoxical bronchospasm. - Cardiac arrhythmias. - Severe allergic reactions (anaphylaxis, angioedema). - Hyperglycemia in susceptible patients. - Acute urinary retention (in patients with prostatic hypertrophy).

Before using Ipratropium + Fenoterol Farmak, consider the following safety points.

Avoid use in patients with known hypersensitivity to either component. Monitor cardiac status in patients with arrhythmias or coronary disease. Use caution in patients with uncontrolled diabetes, as β2‑agonists may raise blood glucose. Assess for urinary retention risk in men with prostate enlargement. Do not exceed prescribed frequency; overuse can increase systemic exposure. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Ipratropium + Fenoterol Farmak may interact with several medication classes.

Major Interactions (Avoid): - Non‑selective β‑blockers: may blunt bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants: risk of severe hypertension. - Potassium‑sparing diuretics (e.g., spironolactone): may increase risk of hyperkalemia when combined with β2‑agonists.

Moderate Interactions (Monitor Closely):\n- Diuretics (e.g., furosemide): may enhance hypokalemia. - Theophylline: additive stimulant effect on the heart. - Anticholinergic drugs (e.g., atropine): may increase anticholinergic side effects. - Corticosteroids: monitor for increased risk of oral thrush when used together.